Evropska unija -
slovenščina -
EMA (European Medicines Agency)
mayzent
novartis europharm limited - siponimod fumaric acid - multiplo sklerozo, recidivno-nakazila - selektivni imunosupresivi - mayzent je indiciran za zdravljenje odraslih bolnikov s sekundarno progresivno multiplo sklerozo (spms), ki imajo aktivno bolezen, dokazuje zagonov ali slikovne funkcije vnetne aktivnosti.
Evropska unija -
slovenščina -
EMA (European Medicines Agency)
fingolimod accord
accord healthcare s.l.u. - fingolimod hidroklorid - multiplo sklerozo, recidivno-nakazila - imunosupresivi, selektivno imunosupresivi - navedeno kot eno bolezen spreminjanje terapije v zelo aktivna recidivno nakazila multiplo sklerozo, za naslednje skupine odraslih bolnikov in pediatričnih bolnikih, starih 10 let in več:bolniki z zelo aktivna bolezen kljub popolno in ustrezno tečaj zdravljenja z vsaj eno bolezen spreminjanje therapyorpatients s hitro razvijajočimi se hudo recidivno nakazila multiplo sklerozo, opredeljeno z 2 ali več onemogočanje zagonov v enem letu, in z 1 ali več gadolinium krepitev poškodbe na možganih, mri ali znatno povečanje t2 lezije obremenitvi, kot je v primerjavi s predhodnim zadnjih mri.
Evropska unija -
slovenščina -
EMA (European Medicines Agency)
fingolimod mylan
mylan ireland limited - fingolimod hidroklorid - multiplo sklerozo, recidivno-nakazila - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 in 5. 1)orpatients s hitro razvijajočimi se hudo recidivno nakazila multiplo sklerozo, opredeljeno z 2 ali več onemogočanje zagonov v enem letu, in z 1 ali več gadolinium krepitev poškodbe na možganih, mri ali znatno povečanje t2 lezije obremenitvi, kot je v primerjavi s predhodnim zadnjih mri.
Evropska unija -
slovenščina -
EMA (European Medicines Agency)
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomide - multiplo sklerozo, recidivno-nakazila - imunosupresivi - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).
Evropska unija -
slovenščina -
EMA (European Medicines Agency)
teriflunomide accord
accord healthcare s.l.u. - teriflunomide - multiplo sklerozo, recidivno-nakazila - imunosupresivi, selektivno imunosupresivi - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
Evropska unija -
slovenščina -
EMA (European Medicines Agency)
zinbryta
biogen idec ltd - daclizumab - multiple skleroza - imunosupresivi - zdravilo zinbryta je indicirano pri odraslih bolnikih za zdravljenje recidivnih oblik multiple skleroze (rms).